October 2014 Issue of The Pathologist

From academic to clinical pathology, microbiology to molecular pathology, we promise to report on the issues and innovations at the heart of your field.

The sequencing of 99 Ebola genomes has not only highlighted the likelihood of viral adaption, but also the high risks for researchers.

Plans to regulate laboratory developed tests could stifle innovation.

Despite numerous research efforts, schizophrenia remains a bit of a mystery.

Low levels of vitamin D may be linked to schizophrenia risk

Could identification of a new biomarker offer hope for mothers?

We know mycobacteria can survive in the absence of oxygen. But what is their secret?

Pathological complete response can provide valuable information on survival in breast cancer, but is a standard definition within reach?

Can SERS accurately detect the early stages of the most common male cancer?

Digital pathology is pushing the boundaries of convention and dividing the community. Uptake of the technology is growing, but only slowly.

Marcial Garcia Rojo of the Hospital de Jerez de la Frontera, Cadiz, Spain, is a key proponent and early adopter of digital pathology, having used the approach for more than seven years.

Matthew Burke, Perry van Rijsingen and Olga Colgan offer their perspectives on digital pathology adoption and the future of the field.

Now more than 90 percent complete, this project could prove invaluable for medical research.

When the two proteome maps appeared in Nature, the numbers certainly raised some eyebrows.

Is the accurate identification of tumor types during surgery – in real-time – a realistic possibility or a pipe dream?

Best practice guidance to ensure that molecular pathology labs get the best possible result

Processes and key considerations when conducting a molecular pathology test for cancer patients.

Pathologists in high-throughput laboratories are working as fast as they can to return results as quickly as possible.

Inadequacy of course content, lack of awareness, poor perception, changing healthcare priorities – it’s no wonder pathology is struggling to attract new talent.

Sitting Down With… Stephen Minger, Chief Scientist, Cellular Sciences – Life Sciences, GE Healthcare, London, UK